Cargando…

Exploring the potential targets of the Abrus cantoniensis Hance in the treatment of hepatitis E based on network pharmacology

Hepatitis E is a disease of public health significance caused by the cross-species transmission of zoonotic hepatitis E virus (HEV) infection. There are no specific drugs. In this study, network pharmacology was used to reveal the mechanism of treatment of the active constituents of the Abrus canton...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Ziheng, Wang, Can, Luan, Zuxiang, Zhang, Dapei, Dong, Baiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076809/
https://www.ncbi.nlm.nih.gov/pubmed/37035802
http://dx.doi.org/10.3389/fvets.2023.1155677
_version_ 1785020216565039104
author Xu, Ziheng
Wang, Can
Luan, Zuxiang
Zhang, Dapei
Dong, Baiqing
author_facet Xu, Ziheng
Wang, Can
Luan, Zuxiang
Zhang, Dapei
Dong, Baiqing
author_sort Xu, Ziheng
collection PubMed
description Hepatitis E is a disease of public health significance caused by the cross-species transmission of zoonotic hepatitis E virus (HEV) infection. There are no specific drugs. In this study, network pharmacology was used to reveal the mechanism of treatment of the active constituents of the Abrus cantoniensis Hance on hepatitis E. Based on the previously published representative components of A. cantoniensis Hance, we were screened the active components with OB ≥ 20% and DL ≥ 0.1 in A. cantoniensis Hance based on the TCMSP, predicted the target online through Swiss target prediction, and integrated the hepatitis E target in the GeneCards and DisGenet databases. Then, the core target was screened and the GO and KEGG enrichment and the network of the drug-active-ingredient-disease-pathway-target analysis were performed by the Cytoscape software. There were 11,046 hepatitis E targets, including PI3K-AKt, SRC, MAPK, PTPN11, EGFR, STAT1 and so on. The core ingredients include Oleanolic acid, Butin, β-sitosterol, Soyasapogenol E, 5,7-dihydroxy-2-methyl-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one, Stigmasterol, Emodin, Physcion, and Enoxolone. A total of 1,410 GO enrichment results of core targets, including 1,246 biological process, 51 cell composition and 113 molecular function results. KEGG pathway was enriched in 150 related pathways, suggesting that A. cantoniensis Hance acts on cancer signaling pathway, endocrine resistance pathway, PI3K-AKt signaling pathway, MAPK, TNF and other signaling pathway. Through key components such as Oleanolic acid, Butin, β-sitosterol, Stigmasterol, and Enoxolone and other components interferes with AKT1, IL-6 and TNF, and regulates pathway in cancer, PI3K-AKt signaling pathway and MAPK pathway to play a therapeutic role in hepatitis E.
format Online
Article
Text
id pubmed-10076809
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100768092023-04-07 Exploring the potential targets of the Abrus cantoniensis Hance in the treatment of hepatitis E based on network pharmacology Xu, Ziheng Wang, Can Luan, Zuxiang Zhang, Dapei Dong, Baiqing Front Vet Sci Veterinary Science Hepatitis E is a disease of public health significance caused by the cross-species transmission of zoonotic hepatitis E virus (HEV) infection. There are no specific drugs. In this study, network pharmacology was used to reveal the mechanism of treatment of the active constituents of the Abrus cantoniensis Hance on hepatitis E. Based on the previously published representative components of A. cantoniensis Hance, we were screened the active components with OB ≥ 20% and DL ≥ 0.1 in A. cantoniensis Hance based on the TCMSP, predicted the target online through Swiss target prediction, and integrated the hepatitis E target in the GeneCards and DisGenet databases. Then, the core target was screened and the GO and KEGG enrichment and the network of the drug-active-ingredient-disease-pathway-target analysis were performed by the Cytoscape software. There were 11,046 hepatitis E targets, including PI3K-AKt, SRC, MAPK, PTPN11, EGFR, STAT1 and so on. The core ingredients include Oleanolic acid, Butin, β-sitosterol, Soyasapogenol E, 5,7-dihydroxy-2-methyl-8-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one, Stigmasterol, Emodin, Physcion, and Enoxolone. A total of 1,410 GO enrichment results of core targets, including 1,246 biological process, 51 cell composition and 113 molecular function results. KEGG pathway was enriched in 150 related pathways, suggesting that A. cantoniensis Hance acts on cancer signaling pathway, endocrine resistance pathway, PI3K-AKt signaling pathway, MAPK, TNF and other signaling pathway. Through key components such as Oleanolic acid, Butin, β-sitosterol, Stigmasterol, and Enoxolone and other components interferes with AKT1, IL-6 and TNF, and regulates pathway in cancer, PI3K-AKt signaling pathway and MAPK pathway to play a therapeutic role in hepatitis E. Frontiers Media S.A. 2023-03-23 /pmc/articles/PMC10076809/ /pubmed/37035802 http://dx.doi.org/10.3389/fvets.2023.1155677 Text en Copyright © 2023 Xu, Wang, Luan, Zhang and Dong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Xu, Ziheng
Wang, Can
Luan, Zuxiang
Zhang, Dapei
Dong, Baiqing
Exploring the potential targets of the Abrus cantoniensis Hance in the treatment of hepatitis E based on network pharmacology
title Exploring the potential targets of the Abrus cantoniensis Hance in the treatment of hepatitis E based on network pharmacology
title_full Exploring the potential targets of the Abrus cantoniensis Hance in the treatment of hepatitis E based on network pharmacology
title_fullStr Exploring the potential targets of the Abrus cantoniensis Hance in the treatment of hepatitis E based on network pharmacology
title_full_unstemmed Exploring the potential targets of the Abrus cantoniensis Hance in the treatment of hepatitis E based on network pharmacology
title_short Exploring the potential targets of the Abrus cantoniensis Hance in the treatment of hepatitis E based on network pharmacology
title_sort exploring the potential targets of the abrus cantoniensis hance in the treatment of hepatitis e based on network pharmacology
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10076809/
https://www.ncbi.nlm.nih.gov/pubmed/37035802
http://dx.doi.org/10.3389/fvets.2023.1155677
work_keys_str_mv AT xuziheng exploringthepotentialtargetsoftheabruscantoniensishanceinthetreatmentofhepatitisebasedonnetworkpharmacology
AT wangcan exploringthepotentialtargetsoftheabruscantoniensishanceinthetreatmentofhepatitisebasedonnetworkpharmacology
AT luanzuxiang exploringthepotentialtargetsoftheabruscantoniensishanceinthetreatmentofhepatitisebasedonnetworkpharmacology
AT zhangdapei exploringthepotentialtargetsoftheabruscantoniensishanceinthetreatmentofhepatitisebasedonnetworkpharmacology
AT dongbaiqing exploringthepotentialtargetsoftheabruscantoniensishanceinthetreatmentofhepatitisebasedonnetworkpharmacology